Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 332


Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States.

Liao SY, Rodgers WH, Kauderer J, Bonfiglio TA, Walker JL, Darcy KM, Carter R, Hatae M, Levine L, Spirtos NM, Stanbridge EJ.

Int J Cancer. 2009 Nov 15;125(10):2434-40. doi: 10.1002/ijc.24615.


Carbonic anhydrase IX (CA-IX) and high-risk human papillomavirus (H-HPV) as diagnostic biomarkers of cervical dysplasia/neoplasia in Japanese women with a cytologic diagnosis of atypical glandular cells (AGC): a Gynecologic Oncology Group (GOG) Study.

Liao SY, Rodgers WH, Kauderer J, Bonfiglio TA, Darcy KM, Carter R, Levine L, Spirtos NM, Susumu N, Fujiwara K, Walker JL, Hatae M, Stanbridge EJ.

Br J Cancer. 2011 Jan 18;104(2):353-60. doi: 10.1038/sj.bjc.6606049. Epub 2010 Dec 14.


Endocervical glandular neoplasia associated with lobular endocervical glandular hyperplasia is HPV-independent and correlates with carbonic anhydrase-IX expression: a Gynaecological Oncology Group Study.

Liao SY, Rodgers WH, Kauderer J, Darcy KM, Carter R, Susumu N, Nagao S, Walker JL, Hatae M, Stanbridge EJ.

Br J Cancer. 2013 Feb 19;108(3):613-20. doi: 10.1038/bjc.2012.578. Epub 2013 Jan 8.


A modified Latent Class Model assessment of human papillomavirus-based screening tests for cervical lesions in women with atypical glandular cells: a Gynecologic Oncology Group study.

Carter RL, Kang L, Darcy KM, Kauderer J, Liao SY, Rodgers WH, Walker JL, Lankes HA, Dunn ST, Stanbridge EJ.

Cancer Causes Control. 2012 Dec;23(12):2013-21. doi: 10.1007/s10552-012-0081-0. Epub 2012 Oct 17.


Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.

Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, Koutsky LA.

JAMA. 2002 Oct 9;288(14):1749-57.


Value of HPV-DNA test in women with cytological diagnosis of atypical glandular cells (AGC).

Zeferino LC, Rabelo-Santos SH, Villa LL, Sarian LO, Costa MC, do Amaral Westin MC, de Ângelo-Andrade LA, Derchain S.

Eur J Obstet Gynecol Reprod Biol. 2011 Nov;159(1):160-4. doi: 10.1016/j.ejogrb.2011.05.023. Epub 2011 Jun 15.


[Combining high-risk human papillomavirus DNA test and cytological test to detect early cervical dysplasia].

Qian DY, Cen JM, Wang D, Zeng RH, Lin AH, Shu YH, Hong DH, Huang ZH.

Zhonghua Fu Chan Ke Za Zhi. 2006 Jan;41(1):34-7. Chinese.


Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection.

Nieves L, Enerson CL, Belinson S, Brainard J, Chiesa-Vottero A, Nagore N, Booth C, Pérez AG, Chávez-Avilés MN, Belinson J.

Int J Gynecol Cancer. 2013 Mar;23(3):513-8. doi: 10.1097/IGC.0b013e318280f3bc.


Prediction of high-grade cervical disease with human papillomavirus detection in women with glandular and squamous cytologic abnormalities.

de Oliveira ER, Derchain SF, Sarian LO, Rabelo-Santos SH, Gontijo RC, Yoshida A, Andrade LA, Zeferino LC.

Int J Gynecol Cancer. 2006 May-Jun;16(3):1055-62.


Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.

Arbyn M, Roelens J, Simoens C, Buntinx F, Paraskevaidis E, Martin-Hirsch PP, Prendiville WJ.

Cochrane Database Syst Rev. 2013 Mar 28;(3):CD008054. doi: 10.1002/14651858.CD008054.pub2. Review.


Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China.

Pan QJ, Hu SY, Guo HQ, Zhang WH, Zhang X, Chen W, Cao J, Jiang Y, Zhao FH, Qiao YL.

Gynecol Oncol. 2014 May;133(2):172-9. doi: 10.1016/j.ygyno.2014.03.008. Epub 2014 Mar 11.


Sensitivity of high-risk HPV Hybrid Capture II (hrHPV HC2) test using SurePath(TM) specimens in the prediction of cervical high-grade squamous lesions.

Zhou F, Pulinthanathu R, Elgert P, Cangiarella J, Simsir A.

Diagn Cytopathol. 2015 May;43(5):381-7. doi: 10.1002/dc.23243. Epub 2014 Dec 26.


Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.

Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM.

Lancet Oncol. 2011 Sep;12(9):880-90. doi: 10.1016/S1470-2045(11)70188-7. Epub 2011 Aug 22.


Comparison of the hybrid capture II assay with the human papillomavirus DNA chip test for the detection of high-grade cervical lesions.

Kang WD, Kim CH, Cho MK, Kim JW, Kim YH, Choi HS, Kim SM.

Int J Gynecol Cancer. 2009 Jul;19(5):924-8. doi: 10.1111/IGC.0b013e3181a832a2.


The clinical value of digene hybrid capture HPV DNA testing in a referral-based population with abnormal pap smears.

Recio FO, Sahai Srivastava BI, Wong C, Hempling RE, Eltabbakh GH, Piver MS.

Eur J Gynaecol Oncol. 1998;19(3):203-8.


Makorin Ring Finger Protein 1 as Adjunctive Marker in Liquid-based Cervical Cytology.

Lee M, Chang MY, Shin HY, Shin E, Hong SW, Kim KM, Chay DB, Cho H, Kim JH.

Medicine (Baltimore). 2016 Jan;95(3):e2425. doi: 10.1097/MD.0000000000002425.


Clinical performance of the Food and Drug Administration-Approved high-risk HPV test for the detection of high-grade cervicovaginal lesions.

Zhou H, Mody RR, Luna E, Armylagos D, Xu J, Schwartz MR, Mody DR, Ge Y.

Cancer Cytopathol. 2016 May;124(5):317-23. doi: 10.1002/cncy.21687. Epub 2016 Jan 15.


Quantitative analysis of methylation status of the PAX1 gene for detection of cervical cancer.

Huang TH, Lai HC, Liu HW, Lin CJ, Wang KH, Ding DC, Chu TY.

Int J Gynecol Cancer. 2010 May;20(4):513-9. doi: 10.1111/IGC.0b013e3181c7fe6e.


Supplemental Content

Support Center